BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CL. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. Clin Breast Cancer 2014;14:228-34. [PMID: 24703985 DOI: 10.1016/j.clbc.2014.02.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Ding S, Xiong J, Lei D, Zhu XL, Zhang HJ. Recombinant nanocomposites by the clinical drugs of Abraxane® and Herceptin® as sequentially dual-targeting therapeutics for breast cancer. J Cancer 2018;9:502-11. [PMID: 29483955 DOI: 10.7150/jca.22163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gadi VK, Davidson NE. Practical Approach to Triple-Negative Breast Cancer. J Oncol Pract 2017;13:293-300. [PMID: 28489980 DOI: 10.1200/JOP.2017.022632] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 6.6] [Reference Citation Analysis]
3 Huang L, Chen S, Yao L, Liu G, Wu J, Shao Z. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. Int J Nanomedicine 2015;10:1969-75. [PMID: 25792830 DOI: 10.2147/IJN.S77000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
4 Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Manag Res 2018;10:91-103. [PMID: 29391830 DOI: 10.2147/CMAR.S146658] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
5 Ghosh A, Upadhyay P, Sarker S, Das S, Bhattacharjee M, Bhattacharya S, Ahir M, Guria S, Gupta P, Chattopadhyay S, Ghosh S, Adhikari S, Adhikary A. Delivery of novel coumarin-dihydropyrimidinone conjugates through mixed polymeric nanoparticles to potentiate therapeutic efficacy against triple-negative breast cancer. Biomater Sci 2021;9:5665-90. [PMID: 34259681 DOI: 10.1039/d1bm00424g] [Reference Citation Analysis]
6 Van de Wiel M, Dockx Y, Van den Wyngaert T, Stroobants S, Tjalma WAA, Huizing MT. Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties. Eur J Obstet Gynecol Reprod Biol 2017;210:144-56. [PMID: 28039758 DOI: 10.1016/j.ejogrb.2016.12.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
7 Spence T, De Souza R, Dou Y, Stapleton S, Reilly RM, Allen C. Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies. J Control Release 2015;219:295-312. [PMID: 26403800 DOI: 10.1016/j.jconrel.2015.09.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bhushan B, Khanadeev V, Khlebtsov B, Khlebtsov N, Gopinath P. Impact of albumin based approaches in nanomedicine: Imaging, targeting and drug delivery. Advances in Colloid and Interface Science 2017;246:13-39. [DOI: 10.1016/j.cis.2017.06.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
9 Omidi Y, Mobasher M, Castejon A, Mahmoudi M. Recent advances in nanoscale targeted therapy of HER2-positive breast cancer. J Drug Target 2022;:1-48. [PMID: 35321601 DOI: 10.1080/1061186X.2022.2055045] [Reference Citation Analysis]
10 Schettini F, Giuliano M, De Placido S, Arpino G. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treat Rev 2016;50:129-41. [PMID: 27665540 DOI: 10.1016/j.ctrv.2016.09.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
11 Shimada H, Ueda S, Saeki T, Shigekawa T, Takeuchi H, Hirokawa E, Sugitani I, Sugiyama M, Takahashi T, Matsuura K, Yamane T, Kuji I, Hasebe T, Osaki A. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety. Jpn J Clin Oncol 2015;45:642-9. [PMID: 25989989 DOI: 10.1093/jjco/hyv055] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
12 Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast 2015;24 Suppl 2:S36-40. [PMID: 26253813 DOI: 10.1016/j.breast.2015.07.009] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 8.9] [Reference Citation Analysis]
13 Zong Y, Wu J, Shen K. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget 2017;8:17360-72. [PMID: 28061451 DOI: 10.18632/oncotarget.14477] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
14 Seki H, Higeta K, Sakurai T, Sakurada A, Kinoshita T, Shimizu K. Feasibility Study of Nanoparticle Albumin-Bound-Paclitaxel and S-1 Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer: A Prospective Study. Clin Breast Cancer 2021:S1526-8209(21)00152-X. [PMID: 34289949 DOI: 10.1016/j.clbc.2021.06.006] [Reference Citation Analysis]
15 Brufsky A. nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings. Exp Hematol Oncol 2017;6:7. [PMID: 28344858 DOI: 10.1186/s40164-017-0066-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
16 Ma X, Wang X, Huang J, Chen Y, Zhang J, Zhang B, Shi C, Liu L. Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis. PLoS One 2016;11:e0160148. [PMID: 27579484 DOI: 10.1371/journal.pone.0160148] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
17 Nan ML, Wang X, Li HJ, Yu DH, Sun WY, Xu HM, He YF, Zhao QC. Rotundic acid induces Cas3-MCF-7 cell apoptosis through the p53 pathway. Oncol Lett 2019;17:630-7. [PMID: 30655810 DOI: 10.3892/ol.2018.9616] [Reference Citation Analysis]
18 Li ZH, Gao J, Hu PH, Xiong JP. Anticancer effects of liriodenine on the cell growth and apoptosis of human breast cancer MCF-7 cells through the upregulation of p53 expression. Oncol Lett 2017;14:1979-84. [PMID: 28781641 DOI: 10.3892/ol.2017.6418] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]